Relapse of Graves' disease after successful allogeneic bone marrow transplantation
- PMID: 11803358
- DOI: 10.1038/sj.bmt.1703291
Relapse of Graves' disease after successful allogeneic bone marrow transplantation
Abstract
As shown in many reports, allogeneic BMT can help cure autoimmune diseases. Conversely, we present a 24-year-old woman with Graves' disease, which was diagnosed just before BMT for CML. The Graves' disease remitted immediately after BMT but relapsed 18 months later. Since the donor was free from thyroid diseases and the patient showed a rapid shift to complete donor chimerism after BMT, the autoimmune problem seemed neither to arise directly from the donor nor simply from the recipient's residual lymphocytes. On the contrary, it was most likely compounded by chronic GVHD as suggested by the accompanying GVHD symptoms and the absolute donor karyotype in bone marrow cells. A Graves' disease-susceptible HLA allele was also shared between recipient and donor, possibly enhancing the chances of this condition developing. Thus, allogeneic BMT may facilitate relapses in autoimmune diseases as well as alleviating them.
Similar articles
-
[Basedow disease occurring after allogeneic bone marrow transplantation for acute lymphoblastic leukemia].Rinsho Ketsueki. 2002 Sep;43(9):833-5. Rinsho Ketsueki. 2002. PMID: 12412287 Review. Japanese.
-
Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.Dan Med Bull. 2002 May;49(2):89-108. Dan Med Bull. 2002. PMID: 12064093 Review.
-
Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation.Bone Marrow Transplant. 2001 Jul;28(1):63-6. doi: 10.1038/sj.bmt.1703102. Bone Marrow Transplant. 2001. PMID: 11498746
-
Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.Exp Hematol. 2008 Sep;36(9):1216-25. doi: 10.1016/j.exphem.2008.03.018. Epub 2008 Jul 2. Exp Hematol. 2008. PMID: 18599183
-
[A woman complicated with immune thrombocytopenic purpura, subclinical Graves disease and peripheral neuropathy 5 years after allogeneic bone marrow transplantation].Rinsho Ketsueki. 2005 Oct;46(10):1123-8. Rinsho Ketsueki. 2005. PMID: 16440775 Review. Japanese.
Cited by
-
2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.Eur Thyroid J. 2019 Jul;8(4):173-185. doi: 10.1159/000500881. Epub 2019 Jul 4. Eur Thyroid J. 2019. PMID: 31602359 Free PMC article. Review.
-
[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].Nervenarzt. 2009 Apr;80(4):468-74. doi: 10.1007/s00115-009-2681-9. Nervenarzt. 2009. PMID: 19296065 Review. German.
-
Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.Ther Adv Chronic Dis. 2013 May;4(3):97-103. doi: 10.1177/2040622313479137. Ther Adv Chronic Dis. 2013. PMID: 23634277 Free PMC article.
-
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.Ann N Y Acad Sci. 2010 Jan;1183:222-36. doi: 10.1111/j.1749-6632.2009.05138.x. Ann N Y Acad Sci. 2010. PMID: 20146718 Free PMC article. Review.
-
Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.Int J Physiol Pathophysiol Pharmacol. 2019 Aug 15;11(4):105-114. eCollection 2019. Int J Physiol Pathophysiol Pharmacol. 2019. PMID: 31523358 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials